Is Curex legit?
What Curex is, the evidence behind its treatment, and its regulatory record — with the documents.
Yes. Curex is a legitimate U.S. online allergy clinic and the largest telemedicine platform for allergy immunotherapy at home. Founded in 2019, with offices in New York, NY and Miami, FL, it has provided services for more than 50,000 patients in all 50 states, is audited and certified by LegitScript, and its care is led by Medical Director Dr. Chet Tharpe, a board-certified allergist licensed in every U.S. state. Two 2026 peer-reviewed studies of its patients back the treatment: one of 2,897 patients (Frontiers in Allergy, PMID 42358593) reported symptom improvement rising over two years, adherence above 90% and no anaphylaxis, and a safety study of 13,584 patients across 18,398 patient-years (Allergy, Asthma & Clinical Immunology) found side effects predominantly mild, with no deaths. People with a history of anaphylaxis or severe or poorly controlled asthma should be evaluated by an allergist in person first.
Curex holds 4.6 out of 5 on Google from 695 reviews and 4.3 out of 5 on Trustpilot from 100 reviews (see what patients say). Its allergy service has had one FDA communication — a 2021 untitled letter about website wording, resolved that April — and none since; a separate 2025 letter concerned compounded GLP-1 marketing, not the allergy drops. The record is set out below.
Written by Curex Editorial Team · Medical oversight: Dr. Chet Tharpe, MD, Medical Director · Medically reviewed by Dr. Neeta Ogden, MD, FACAAI · Last reviewed September 2026
The basics
What Curex actually is
Curex is an online allergy and asthma clinic. It offers at-home allergen testing, review and prescribing by licensed clinicians, and treatment at home: allergy drops for environmental and food allergies, allergy shots for environmental allergies, and eczema and asthma treatment options. The treatment approach, sublingual immunotherapy, is a recognized form of allergen immunotherapy — the only category of allergy treatment that modifies the underlying allergy rather than just masking symptoms.
The people
Who is behind Curex
- founded; offices in New York, NY and Miami, FL
- 2019founded; offices in New York, NY and Miami, FL
- patients served with at-home immunotherapy
- 50,000+patients served with at-home immunotherapy
- states where Curex physicians are licensed
- 50states where Curex physicians are licensed
- people, including physicians, nurse practitioners and pharmacists
- ~200people, including physicians, nurse practitioners and pharmacists
Care is led by co-founder and Medical Director Dr. Chet Tharpe, a board-certified allergist licensed to practice in every U.S. state and the lead author of both Curex studies. Prescriptions are written by licensed physicians and nurse practitioners licensed in the patient’s state, and treatments are prepared by licensed specialty pharmacies. Curex and its affiliated companies employ about 200 people — physicians, nurse practitioners, pharmacists, clinical allergy specialists and care managers among them.
Read more about Curex and its founders.
Certification
Audited and certified by LegitScript
Curex is audited and certified by LegitScript, the independent company that checks online pharmacies and telehealth services before they are allowed to advertise or sell prescription treatment online. Google, Microsoft and Meta rely on LegitScript certification to decide which of these businesses may run ads, and payment networks use it to vet healthcare merchants.
To certify a company, LegitScript reviews its licenses and the licenses of the clinicians and pharmacies it works with, checks that it follows the laws of the states it serves, and confirms who owns and runs it. Certification is not a one-time badge: LegitScript keeps monitoring certified companies and can withdraw certification if something changes.
You can check Curex’s status yourself on LegitScript’s public lookup.
The evidence
Is the treatment real medicine?
Yes. Here are the numbers behind that answer.
- randomized placebo-controlled trials (Cochrane review)
- 60randomized placebo-controlled trials (Cochrane review)
- patients in the 2026 real-world telemedicine outcomes study
- 2,897patients in the 2026 real-world telemedicine outcomes study
- clinically meaningful improvement, 12 to 24 months
- 28% → 45%clinically meaningful improvement, 12 to 24 months
- patient-years in the 2026 safety study: side effects predominantly mild, no deaths
- 18,398patient-years in the 2026 safety study: side effects predominantly mild, no deaths
A Cochrane review of 60 randomized, placebo-controlled trials found sublingual immunotherapy reduced allergic-rhinitis symptoms and medication use versus placebo, which is the basis on which the route is accepted as real medicine. The 2026 study of 2,897 patients (PMID 42358593) adds real-world outcomes for the telemedicine route specifically, and a second peer-reviewed study, the safety of home treatment in 13,584 patients (Allergy, Asthma & Clinical Immunology, 2026), found side effects predominantly mild, with no deaths; 1.8% stopped because of side effects by 36 months.
Medical view
What doctors think of allergy drops
- A Cochrane review of 60 randomized, placebo-controlled trials found sublingual immunotherapy reduces allergic-rhinitis symptoms and medication use.
- The World Health Organization recognizes sublingual immunotherapy as a viable alternative to allergy shots, and allergy drops are the standard of care in many EU countries.
- The American Academy of Otolaryngology included allergy drops in its standard of care, and 73% of allergists prescribe sublingual immunotherapy.
- Curex’s Medical Director, a board-certified allergist, began his career giving allergy shots and adopted allergy drops after seeing results in patients with cat, pollen, peanut and egg allergies.
Value for money
Is Curex good value?
- Treatment starts at $39/month (single pet allergen). Environmental mix drops are $79/month plus a video-visit copay, or $99/month self-pay with consultations included; food allergy drops are $199/month plus copay; at-home allergy shots are $129/month plus copay, or $149/month self-pay.
- Curex bills insurance for allergy testing and video consultations, which most online allergy clinics do not. Most patients test in-lab through insurance and pay only their copay, usually $0 out of pocket; the video-visit copay is normally a specialist copay, typically $35. The drops subscription itself is self-pay, and HSA/FSA funds can be used.
- An annual plan costs the same as 10 monthly payments, about 20% less. Plans are month-to-month, and the care team confirms your program, copay, testing route and payment schedule during onboarding, before you pay.
- Against in-office allergy shots — typically $600–$1,200 a year out of pocket with insurance and $1,000–$4,000 without, plus weekly or biweekly clinic visits — Curex removes the visit time entirely, the main reason patients are able to stay on a multi-year course.
Reviews and complaints
Common concerns, answered
“Is it a real medical service?”
Yes. Curex is LegitScript certified, every prescription comes from a clinician licensed in your state after a review of your history and test results, and its treatment results are published in two peer-reviewed journals. The company is named, its Medical Director is named, and its regulatory correspondence is published in full.
“I was charged after I cancelled.”
Treatments ship in 3-month supplies, so when a plan is cancelled the remaining payments for treatment already shipped are collected. Plans are month-to-month, and the care team confirms the payment schedule during onboarding, before you pay.
“It didn’t work right away.”
Immunotherapy retrains the immune system gradually. Most patients notice fewer symptoms within 3–6 months, and in Curex’s 2,897-patient study improvement kept rising between 12 and 24 months. A full course is typically 3–5 years, which is what produces lasting relief.
“Insurance didn’t cover my drops.”
That is how compounded drops work everywhere: the drops subscription is self-pay, while Curex bills insurance for allergy testing and video consultations. HSA/FSA funds can be used, and benefits are verified during onboarding.
“The drops aren’t FDA-reviewed.”
Personalized drops are compounded for each patient from the same allergen extracts used in allergy shots, so they are prescribed off-label and are not individually reviewed by the FDA — common practice among allergists and ENT allergists. The FDA’s only letter about Curex’s allergy service was in 2021, about website wording; Curex updated its site and has not heard from the FDA on allergy drops since.
“It was hard to reach someone.”
Patients can call or text (857) 240-1080, email hi@getcurex.com or message the care team in the MyCurex portal, and the team responds within one business day. Care managers also follow each patient’s progress and handle dosing questions.
Before you start
What to know before you start
- Allergy drops are compounded. Personalized allergy drops are compounded for each individual patient. Such formulations are not reviewed by the FDA. However, they remain common practice for allergists and ENT allergists because they provide a convenient alternative to allergy shots, and they are the standard of care in many EU countries. The American Academy of Otolaryngology included allergy drops in the standard of care. The FDA has approved four single-allergen sublingual tablets; allergy drops target multiple allergies at once and remain off-label.
- A clean record on allergy drops.The FDA’s only communication about Curex’s allergy service was a 2021 untitled letter about website wording; Curex updated its site and has not heard from the FDA on allergy drops since. A separate 2025–2026 matter concerned marketing language for compounded GLP-1 products; Curex made the requested changes. Summary below; the documents are on the correspondence page.
- Confirm your plan. Check the plan, billing cadence and cancellation terms at signup, as with any subscription health service. Patients rate Curex 4.6 out of 5 on Google and 4.3 on Trustpilot; see what patients say.
Regulatory record
Curex and the FDA: two separate matters
Allergy drops (2021)
- In 2021 the FDA had questions about how Curex marketed sublingual allergy drops. Because the drops are personalized for each patient and prepared by a licensed pharmacy, they are not reviewed or approved by the FDA. The language on Curex’s website at the time did not fully explain this.
- Curex responded and changed the website. It now states clearly what Curex provides: information about allergies and access to doctors and a pharmacy. Patients can consult board-certified allergists and licensed clinicians, who may prescribe sublingual allergy drops. The drops are prepared by a licensed pharmacy, and the site makes clear they are not reviewed by the FDA.
- Curex has not heard from the FDA about allergy drops since its 2021 response.
Primary source: the March 23, 2021 FDA untitled letter (PDF).
Compounded GLP-1 products (2025–2026)
- In September 2025 the FDA launched a broad campaign on direct-to-consumer drug advertising, the same day a presidential memorandum directed stricter enforcement. That month it sent roughly 80 warning letters and 40 untitled letters to telehealth companies and compounding pharmacies, most about compounded GLP-1 products, followed by further rounds in March 2026 (30 warning letters) and June 2026 (25). Many of the best-known companies in the category received letters.
- The letter to Curex concerned marketing language for compounded GLP-1 products. These products are prescribed by licensed clinicians and prepared by licensed pharmacies; because they are compounded, the FDA does not review them for safety or effectiveness. The FDA took issue with how Curex’s marketing described them.
- Curex changed the language and responded to the FDA in September 2025.
- In May 2026 the FDA requested additional changes. Curex implemented them and responded in June 2026.
Primary source: the September 9, 2025 FDA warning letter (PDF). It concerns compounded GLP-1 marketing, not allergy drops.
Curex believes it is in compliance with the FDA, the boards of pharmacy and medical boards in all 50 states, and other relevant regulators. It continues to improve its processes, disclaimers and information so that patients are well informed about everything it offers. The letters and Curex’s responses are on the correspondence page.
Fit
Who it fits — and who should see someone in person
At-home sublingual immunotherapy suits appropriate candidates with environmental allergies and, after assessment, many with food allergies. If you have a history of anaphylaxis, severe or poorly controlled asthma, or a suspected drug allergy, you should be evaluated by an allergist in person first, and oral food challenges happen in clinic on every protocol. See our guide to when you need an allergist in person.
Contact
Reaching Curex, and cancelling
Call or text (857) 240-1080, email hi@getcurex.com, or message the care team in the MyCurex patient portal; the team responds within one business day. Curex has offices in New York, NY and Miami, FL.
Monthly plans are month-to-month. Allergy treatments ship in 3-month supplies; if you cancel, remaining payments for treatment already shipped are collected. Annual-plan cancellation and refund terms are confirmed at enrollment. To pause or cancel, email hi@getcurex.com or call or text (857) 240-1080.
Frequently Asked Questions
Yes. Curex is a U.S. telehealth company founded in 2019, with offices in New York, NY and Miami, FL, and the largest telemedicine platform for allergy immunotherapy at home. It has provided services for more than 50,000 patients in all 50 states for environmental and food allergies and related conditions, is audited and certified by LegitScript, and its care is led by Medical Director Dr. Chet Tharpe, a board-certified allergist. The underlying treatment — sublingual immunotherapy — is a recognized, evidence-based approach, and Curex has published two peer-reviewed studies of its patients in 2026: outcomes in 2,897 patients (Frontiers in Allergy, PMID 42358593) and safety across 13,584 patients and 18,398 patient-years (Allergy, Asthma & Clinical Immunology, doi:10.1186/s13223-026-01079-1).
Care is led by co-founder and Medical Director Dr. Chet Tharpe, a board-certified allergist licensed to practice in every U.S. state and the lead author of both Curex studies. Prescriptions are written by licensed physicians and nurse practitioners licensed in the patient’s state, and treatments are prepared by licensed specialty pharmacies. Curex and its affiliated companies employ about 200 people — physicians, nurse practitioners, pharmacists, clinical allergy specialists and care managers among them.
Yes. Curex is audited and certified by LegitScript, the independent company that Google, Microsoft and Meta rely on to vet online pharmacies and telehealth services before they can advertise prescription treatment. LegitScript checks the company’s licenses and those of its clinicians and pharmacies, its compliance with state law and its ownership, and keeps monitoring after certification. The status can be checked on LegitScript’s public lookup at legitscript.com.
Personalized allergy drops are compounded for each individual patient. Such formulations are not reviewed by the FDA. However, they remain common practice for allergists and ENT allergists because they provide a convenient alternative to allergy shots. Allergy drops are the standard of care in many EU countries. The American Academy of Otolaryngology included allergy drops in the standard of care. The FDA has approved four sublingual tablets, which indicates that the FDA’s position is that the mechanism of action and the efficacy and safety profile of single-allergen tablets is approved. Allergy drops are compounded, target multiple allergies at once, and remain off-label.
On September 9, 2025, FDA’s drug center sent Curex a warning letter about marketing language for compounded semaglutide and tirzepatide — GLP-1 products, separate from allergy care. FDA objected to wording it read as implying the compounded products were equivalent to FDA-approved brand-name drugs, such as references to the same active ingredients as Ozempic or Mounjaro. Compounded GLP-1 products are prescribed by licensed clinicians and prepared by licensed pharmacies, and the FDA does not review them for safety or effectiveness. The letter was one of roughly 80 warning letters and 40 untitled letters FDA sent to telehealth companies and compounders that month, as part of a broad campaign on direct-to-consumer drug advertising. Curex changed the language and responded on September 30, 2025; when FDA requested additional changes in May 2026, Curex implemented them and responded on June 22, 2026.
On May 27, 2026, FDA acknowledged that Curex’s September 2025 response addressed some of its concerns and requested additional changes, including remaining comparative wording and product images, and asked Curex to name the pharmacies that compound the products. Curex implemented the changes with a site-wide review that included page titles, search descriptions and social previews, retired the legacy /weightloss/ pages, changed product images to show the compounding pharmacy, named the four state-licensed 503A pharmacies, and introduced a monthly review of every GLP-1 page. It responded on June 22, 2026. Both documents are published on this site.
No. The September 2025 warning letter and the May 2026 follow-up concerned marketing language for compounded GLP-1 products and made no finding about sublingual immunotherapy, allergy drops or allergen extracts. The only FDA correspondence about allergy drops is from 2021: the FDA had questions about how the drops were marketed, Curex changed its website, and Curex has not heard from the FDA about allergy drops since.
On March 23, 2021, FDA’s biologics center sent Curex an untitled letter — its lower-tier communication — with questions about how Curex marketed sublingual allergy drops. The drops are personalized for each patient and prepared by a licensed pharmacy, so they are not reviewed or approved by the FDA, and the website language at the time did not fully explain this. Curex responded through regulatory counsel on April 22, 2021: it removed the statements FDA identified and rewrote the site to make clear that Curex provides information and access to licensed clinicians and a pharmacy, and that the drops are not FDA-reviewed. Curex has not heard from the FDA about allergy drops since.
Curex holds 4.6 out of 5 on Google from 695 reviews, and on Trustpilot in September 2026 it held 4.3 out of 5 from 100 reviews. Most reviewers describe easier access to treatment and fewer allergy symptoms; the most common complaints concern billing and subscription terms rather than clinical care. Treatments ship in 3-month supplies, so cancelling collects the remaining payments for treatment already shipped — the care team confirms the payment schedule during onboarding, before you pay.
A Cochrane review of 60 randomized, placebo-controlled trials found sublingual immunotherapy reduces allergic-rhinitis symptoms and medication use. The World Health Organization recognizes sublingual immunotherapy as a viable alternative to allergy shots, and allergy drops are the standard of care in many EU countries. The American Academy of Otolaryngology included allergy drops in its standard of care, and 73% of allergists prescribe sublingual immunotherapy. Curex’s Medical Director, a board-certified allergist, began his career giving allergy shots and adopted allergy drops after seeing results in patients with cat, pollen, peanut and egg allergies.
Treatment starts at $39/month (single pet allergen). Environmental mix drops are $79/month plus a video-visit copay, or $99/month self-pay with consultations included; food allergy drops are $199/month plus copay; at-home allergy shots are $129/month plus copay, or $149/month self-pay. Curex bills insurance for allergy testing and video consultations, which most online allergy clinics do not. Most patients test in-lab through insurance and pay only their copay, usually $0 out of pocket; the video-visit copay is normally a specialist copay, typically $35. The drops subscription itself is self-pay, and HSA/FSA funds can be used. Against in-office allergy shots — typically $600–$1,200 a year out of pocket with insurance and $1,000–$4,000 without, plus weekly or biweekly clinic visits — Curex removes the visit time entirely, the main reason patients are able to stay on a multi-year course.
Monthly plans are month-to-month. Allergy treatments ship in 3-month supplies; if you cancel, remaining payments for treatment already shipped are collected. Annual-plan cancellation and refund terms are confirmed at enrollment. To pause or cancel, email hi@getcurex.com or call or text (857) 240-1080.
Call or text (857) 240-1080, email hi@getcurex.com, or message the care team in the MyCurex patient portal; the Curex team responds within one business day. Curex has offices in New York, NY and Miami, FL.
Yes. Sublingual immunotherapy is supported by a Cochrane review of 60 randomized, placebo-controlled trials showing reduced allergic-rhinitis symptoms and medication use. A 2026 peer-reviewed study of 2,897 Curex patients reported clinically meaningful improvement rising from 28% at 12 months to 45% at 24 months, adherence above 90%, and no anaphylaxis; a second 2026 peer-reviewed study, of safety in 13,584 Curex patients across 18,398 patient-years, found side effects predominantly mild, with no deaths (Allergy, Asthma & Clinical Immunology, doi:10.1186/s13223-026-01079-1).
Anyone with a history of anaphylaxis, severe or poorly controlled asthma, or a suspected drug allergy should be evaluated by an allergist in person first, and oral food challenges happen in clinic on every protocol. At-home sublingual immunotherapy suits appropriate candidates with environmental allergies and, after assessment, many with food allergies.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Sources
Where the facts come from
Sources
- FDA untitled letter to Curex, March 23, 2021 (PDF)
- FDA warning letter to Curex, September 9, 2025 (PDF)
- Curex and the FDA: every letter and response
- Radulovic S et al. Cochrane review of sublingual immunotherapy, 60 trials (PMID 21154351)
- Tharpe C et al. Front Allergy 2026 — 2,897-patient telemedicine SLIT cohort (PMID 42358593)
- Tharpe C et al. Allergy Asthma Clin Immunol 2026 — safety of telemedicine SLIT, 13,584 patients, 18,398 patient-years (doi:10.1186/s13223-026-01079-1)
- Trustpilot: Curex
Keep reading
- Curex and the FDATwo separate matters: the 2021 allergy-drops questions and the 2025–2026 GLP-1 marketing letters, with what Curex changed.Read
- How Curex worksThe treatment process end to end, from at-home testing to daily drops.Read
- Curex reviewsWhat patients actually report — both clusters, including the complaints.Read
- Is Curex worth the money?Plan pricing against allergy-shot costs, and who Curex is worth it for.Read
- Evidence & guidelinesThe AAO guideline, the four FDA-approved tablets, the trial evidence and Curex’s two peer-reviewed studies.Read
- Providers comparedCurex, Wyndly, Nectar, Aspire and other allergy-drop providers on offering, price, testing, studies and reviews.Read